



- (51) **International Patent Classification:**
C07K 14/54 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/EP2020/050920
- (22) **International Filing Date:**
15 January 2020 (15.01.2020)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
19305046.5 15 January 2019 (15.01.2019) EP
- (71) **Applicants:** INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) [FR/FR]; 101 rue de Tolbiac, 75013 Paris (FR). UNIVERSITÉ DE NANTES [FR/FR]; 1 quai de Tourville, 44000 Nantes (FR).
- (72) **Inventors:** GUILLONNEAU, Carole; 22 rue du Marais, 44118 La Chevrolière (FR). ANEGON, Ignacio; 2A rue du Maine, 44000 Nantes (FR). MORTIER, Erwan; 16 rue des Salorges, 44100 Nantes (FR). QUEMENER, Agnès; 31 rue Marange Sylvanage, 44100 Nantes (FR).
- (74) **Agent:** ICOSA; 83 avenue Denfert-Rochereau, 75014 Paris (FR).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— of inventorship (Rule 4.17(iv))

(54) **Title:** MUTATED INTERLEUKIN-34 (IL-34) POLYPEPTIDES AND USES THEREOF IN THERAPY




Figure 1

(57) **Abstract:** Interleukin-34 is a cytokine that is involved in the differentiation and survival of macrophages, monocytes, and dendritic cells in response to inflammation. The involvement of IL-34 has been shown in areas as diverse as neuronal protection, autoimmune diseases, infection, cancer, and transplantation. Recent work has also demonstrated a new and possible therapeutic role for IL-34 as a Foxp3 + Treg-secreted cytokine mediator of transplant tolerance. The inventors now generated new mutated IL-34 polypeptides that can be used as agonists or antagonists.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*